FDA approves first pill to treat maternal postpartum depression

The FDA approved the first pill (Zurzuvae) to treat postpartum depression in adults, a more accessible option than the only other alternative of an intravenous injection. The CDC found that 1 in 8 women experience symptoms of postpartum depression and that the rate of depression diagnoses at delivery is increasing. The rising prevalence of postpartum depression necessitates accessible treatment options like Zurzuvae.